Altogether, our results displayed that SESN2 was up‐regulated in HCC cells and tissues as a potential promoter for sorafenib primary resistance through simultaneously activating AKT and AMPK to restrain cell apoptosis. Here, SESN2 is linked to hepatocellular carcinoma.